Image via TalecrisBeing a former employee of Talecris I am familiar with the IGIV Gammunex program. This is good news for Talecris (TLCR) as it gains Patent Protection approval for providing viral free blood products to those with ImmunoDeficiency. Those with Immuno Deficiency desperately need Talecris' Life Saving BioPharmaceuticals to its patients. It is a very rewarding job to know that the product you are making is actually saving lives.
Would You Actually Take This Medication If You Had To? That is an important question for a company to ask it's employees. Some places you might not actually do so. That is how bad some companies can get. Talecris is not one of them. They have sophisticated GMP sterile fill lines that have extensive quality controls of their product. I should know, I tested the samples day in and day out. It was a clean, sterile facility designed with Sterilty in mind.
Gamunex is a production is a Bayer Biological Designed facility and Talecris is venture capitalized after being acquired from Bayer.
Talecris---Wikinvest
Talecris does have some of long term debt but that will be reduced after this announcement.
They are a takeover target with this approval in my mind. They did not merge with their Australian counterpart a year ago due to fears of monopolizing the drug market
If you would like more Subscribe To BioPharma Investor for everyday stock news and up to date FDA decisions. Biopharma Investor
See more news releases in: Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, New Products & Services, FDA Approval
Talecris Biotherapeutics Receives FDA Approval for Gamunex®-C
New Subcutaneous Administration Provides another Mode of Delivery For Patients with Primary Immunodeficiency
RESEARCH TRIANGLE PARK , N.C., Oct. 14 /PRNewswire
Talecris Biotherapeutics (Nasdaq: TLCR) announced today that the U.S. Food and Drug Administration (FDA) approved Gamunex®-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency (PI).
